Search research articles
Contact Us
Filters
Showing results (71-80 of 111) with videos related to
Page
of 12
Sort By:
British Journal of Cancer
|
September 28, 2019
Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer
Chitra Joseph, Sara Al-Izzi, Mansour Alsaleem, et al.
Scientific Reports
|
March 14, 2020
A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation
Melpomeni Kalofonou, Kenny Malpartida-Cardenas, George Alexandrou, et al.
Nature
|
January 6, 2012
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
Caryn S Ross-Innes, Rory Stark, Andrew E Teschendorff, et al.
Nucleic Acids Research
|
November 12, 2005
T:G mismatch-specific thymine-DNA glycosylase (TDG) as a coregulator of transcription interacts with SRC1 family members through a novel tyrosine repeat motif
Marie J Lucey, Dongsheng Chen, Jorge Lopez-Garcia, et al.
Nucleic Acids Research
|
October 5, 2017
p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells
Manikandan Periyasamy, Anup K Singh, Carolina Gemma, et al.
Molecular Cancer Therapeutics
|
March 17, 2018
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Hetal Patel, Manikandan Periyasamy, Georgina P Sava, et al.
Nature Medicine
|
May 24, 2011
Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer
Georgios Giamas, Aleksandra Filipović, Jimmy Jacob, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2015
SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer
Wilbert Zwart, Koen D Flach, Bharath Rudraraju, et al.
Nature Genetics
|
May 27, 2017
Corrigendum: Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer
Luca Magnani, Gianmaria Frigè, Raffaella Maria Gadaleta, et al.
British Journal of Cancer
|
April 19, 2023
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
Theodora A Constantin, Anabel Varela-Carver, Kyle K Greenland, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 111) with videos related to
Sort By:
Page
of 12
British Journal of Cancer
|
September 28, 2019
Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer
Chitra Joseph, Sara Al-Izzi, Mansour Alsaleem, et al.
Scientific Reports
|
March 14, 2020
A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation
Melpomeni Kalofonou, Kenny Malpartida-Cardenas, George Alexandrou, et al.
Nature
|
January 6, 2012
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
Caryn S Ross-Innes, Rory Stark, Andrew E Teschendorff, et al.
Nucleic Acids Research
|
November 12, 2005
T:G mismatch-specific thymine-DNA glycosylase (TDG) as a coregulator of transcription interacts with SRC1 family members through a novel tyrosine repeat motif
Marie J Lucey, Dongsheng Chen, Jorge Lopez-Garcia, et al.
Nucleic Acids Research
|
October 5, 2017
p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells
Manikandan Periyasamy, Anup K Singh, Carolina Gemma, et al.
Molecular Cancer Therapeutics
|
March 17, 2018
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Hetal Patel, Manikandan Periyasamy, Georgina P Sava, et al.
Nature Medicine
|
May 24, 2011
Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer
Georgios Giamas, Aleksandra Filipović, Jimmy Jacob, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2015
SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer
Wilbert Zwart, Koen D Flach, Bharath Rudraraju, et al.
Nature Genetics
|
May 27, 2017
Corrigendum: Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer
Luca Magnani, Gianmaria Frigè, Raffaella Maria Gadaleta, et al.
British Journal of Cancer
|
April 19, 2023
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
Theodora A Constantin, Anabel Varela-Carver, Kyle K Greenland, et al.
Page
of 12